Phase III under way

Article

New York - Adjuvant therapy with a macrophage-activating growth factor appears to prolong survival in high-risk melanoma, Lynn E. Spitler, M.D., said.

Related Videos
Related Content

Incyte to Present Numerous Studies at EADV 2023

September 29th 2023

The Cutaneous Connection: Exploring the Effects of Pollutants on Atopic Dermatitis

June 12th 2023

Prolonged Remission in Rosacea: A Breakthrough With Subantibiotic Dose of Oral Doxycycline

September 29th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

DEF and SDPA Partner to Emphasize Cardiovascular Health for World Heart Day

September 29th 2023

Discovering Dermatology Times: September 2023

September 28th 2023

Incyte to Present Numerous Studies at EADV 2023

September 29th 2023

The Cutaneous Connection: Exploring the Effects of Pollutants on Atopic Dermatitis

June 12th 2023

Prolonged Remission in Rosacea: A Breakthrough With Subantibiotic Dose of Oral Doxycycline

September 29th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

DEF and SDPA Partner to Emphasize Cardiovascular Health for World Heart Day

September 29th 2023

Discovering Dermatology Times: September 2023

September 28th 2023

Incyte to Present Numerous Studies at EADV 2023

September 29th 2023

The Cutaneous Connection: Exploring the Effects of Pollutants on Atopic Dermatitis

June 12th 2023

Prolonged Remission in Rosacea: A Breakthrough With Subantibiotic Dose of Oral Doxycycline

September 29th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

DEF and SDPA Partner to Emphasize Cardiovascular Health for World Heart Day

September 29th 2023

Discovering Dermatology Times: September 2023

September 28th 2023
© 2023 MJH Life Sciences

All rights reserved.